Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
EyePoint, Inc. (EYPT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.36-9.90%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for EYPT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Achieve full enrollment by Q3 2026 | The company targets full enrollment in clinical trials by Q3 2026. | Intact | Enrollment falls short of full target by Q3 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making development-stage biotech, not a proven earnings compounder. The long-term thesis is in a watch state: management continues to prioritize DURAVYU Phase 3 development in DME, but the evidence of execution remains limited.
The valuation signal says EYPT is cheap versus peers, but confidence in that comparison is low. The expectations gap is slightly negative, suggesting expectations are not especially demanding; however, that does not remove the risk from continued losses or execution setbacks.
Near term, another earnings miss is a material risk after recent misses, and the overall risk label has risen to high. Management has announced workforce and cost reductions, but the expected savings are not yet reflected in reported results; cash and investments were estimated at $118 million at September 30, below the $180 million reported at June 30. Over the multi-year view, DURAVYU’s DME development remains active, but the evidence snapshot contains no new clinical outcome data.
The thesis hinges on progress in the DME program, delivery of cost savings, and whether cash runway can support development; management’s Q4 2027 runway estimate has not been updated in the October disclosure. Near-term outcomes also depend on the next guidance update and broader Healthcare-sector signals, while weakening employment data could add pressure to cyclical names.
For the next 1 to 3 years, EYPT remains a high-risk development story with a stated clinical priority but limited fresh evidence of delivery, alongside near-term earnings and cash concerns. The thesis depends on execution becoming clearer. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| It aims to fully fund the Phase 3 DME program. |
| Under Pressure |
| Failure to secure full funding for Phase 3 DME program in 2026 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Advance Phase 3 wet AMD program | EyePoint is advancing its Phase 3 wet AMD program. | Under Pressure | Failure to meet key Phase 3 milestones in 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.93 → $-2.13 · observed estimates
$0.04B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.93 | $40,605,099 | 8 / 9 |
| 2026-07-25 | $-3.04 | $32,756,770 | 12 / 14 |
| 2026-07-26 | $-3.04 | $32,756,770 | 12 / 14 |
| 2026-07-27 | $-3.04 | $32,756,770 | 12 / 14 |
| 2026-07-28 | $-3.00 | $32,747,956 | 9 / 9 |
| 2026-07-29 | $-3.00 | $32,747,956 | 9 / 9 |
| 2026-07-30 | $-3.04 | $32,756,770 | 12 / 14 |
| 2026-07-31 | $-3.00 | $32,747,956 | 9 / 9 |
| 2026-08-01 | $-3.00 | $32,747,956 | 9 / 9 |
| 2026-08-02 | $-3.04 | $32,756,770 | 12 / 14 |
| 2026-08-03 | $-3.00 | $32,747,956 | 9 / 9 |
| 2026-08-04 | $-3.04 | $32,756,770 | 12 / 14 |
| 2026-08-05 | $-3.04 | $32,756,770 | 12 / 14 |
| 2026-08-06 | $-3.00 | $32,747,956 | 9 / 9 |
| 2026-08-07 | $-3.01 | $29,467,528 | 9 / 9 |
| 2026-08-08 | $-3.08 | $41,620,430 | 12 / 11 |
| 2026-08-09 | $-3.08 | $41,620,430 | 12 / 11 |
| 2026-08-10 | $-3.08 | $41,620,430 | 12 / 11 |
| 2026-08-11 | $-3.06 | $31,972,850 | 12 / 11 |
| 2026-08-12 | $-3.01 | $29,467,528 | 9 / 9 |
| 2026-08-13 | $-3.03 | $17,190,800 | 12 / 10 |
| 2026-08-14 | $-3.01 | $29,467,528 | 9 / 9 |
| 2026-08-15 | $-3.01 | $29,467,528 | 9 / 9 |
| 2026-08-16 | $-3.01 | $29,467,528 | 9 / 9 |
| 2026-08-17 | $-3.01 | $29,467,528 | 9 / 9 |
| 2026-08-18 | $-3.01 | $29,467,528 | 9 / 9 |
| 2026-08-19 | $-3.01 | $29,467,528 | 9 / 9 |
| 2026-08-20 | $-2.77 | $17,921,913 | 9 / 9 |
| 2026-08-21 | $-2.77 | $17,921,913 | 8 / 8 |
| 2026-08-22 | $-2.77 | $17,921,913 | 9 / 9 |
| 2026-08-23 | $-2.77 | $17,921,913 | 9 / 9 |
| 2026-08-24 | $-2.77 | $17,921,913 | 9 / 9 |
| 2026-08-25 | $-2.77 | $17,921,913 | 9 / 9 |
| 2026-08-26 | $-2.77 | $17,921,913 | 9 / 9 |
| 2026-08-27 | $-2.77 | $17,921,913 | 9 / 9 |
| 2026-08-28 | $-2.77 | $17,921,913 | 9 / 9 |
| 2026-08-29 | $-2.77 | $17,921,913 | 9 / 9 |
| 2026-08-30 | $-2.77 | $17,921,913 | 9 / 9 |
| 2026-08-31 | $-2.77 | $17,921,913 | 9 / 9 |
| 2026-09-01 | $-2.77 | $17,921,913 | 9 / 9 |
| 2026-09-02 | $-2.77 | $17,921,913 | 9 / 9 |
| 2026-09-03 | $-2.73 | $17,921,913 | 9 / 9 |
| 2026-09-04 | $-2.73 | $17,921,913 | 9 / 9 |
| 2026-09-05 | $-2.73 | $17,921,913 | 9 / 9 |
| 2026-09-06 | $-2.73 | $17,921,913 | 9 / 9 |
| 2026-09-07 | $-2.73 | $17,921,913 | 9 / 9 |
| 2026-09-08 | $-2.73 | $17,921,913 | 9 / 9 |
| 2026-09-09 | $-2.73 | $17,921,913 | 9 / 9 |
| 2026-09-10 | $-2.73 | $17,921,913 | 9 / 9 |
| 2026-09-11 | $-2.73 | $17,921,913 | 9 / 9 |
| 2026-09-12 | $-2.73 | $17,921,913 | 9 / 9 |
| 2026-09-13 | $-2.73 | $17,921,913 | 9 / 9 |
| 2026-09-14 | $-2.73 | $17,921,913 | 9 / 9 |
| 2026-09-15 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-09-16 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-09-17 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-09-18 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-09-19 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-09-20 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-09-21 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-09-22 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-09-23 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-09-24 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-09-25 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-09-26 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-09-27 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-09-28 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-09-29 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-09-30 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-10-01 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-10-02 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-10-03 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-10-04 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-10-05 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-10-06 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-10-07 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-10-08 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-10-09 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-10-10 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-10-11 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-10-12 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-10-13 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-10-14 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-10-15 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-10-16 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-10-17 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-10-18 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-10-19 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-10-20 | $-2.73 | $17,925,760 | 9 / 9 |
| 2026-10-21 | $-2.50 | $7,310,882 | 10 / 12 |
| 2026-10-22 | $-2.22 | $7,287,805 | 10 / 12 |
| 2026-10-23 | $-2.22 | $7,287,805 | 10 / 12 |
| 2026-10-24 | $-2.22 | $7,287,805 | 10 / 12 |
| 2026-10-25 | $-2.22 | $7,287,805 | 10 / 12 |
| 2026-10-26 | $-2.22 | $7,287,805 | 10 / 12 |
| 2026-10-27 | $-2.22 | $7,287,805 | 10 / 12 |
| 2026-10-28 | $-2.22 | $7,287,805 | 10 / 12 |
| 2026-10-29 | $-2.22 | $7,287,805 | 10 / 12 |
| 2026-10-30 | $-2.13 | $3,826,267 | 10 / 12 |
| 2026-10-31 | $-2.13 | $3,826,267 | 10 / 12 |
| 2026-11-01 | $-2.13 | $3,826,267 | 10 / 12 |
| 2026-11-02 | $-2.13 | $3,826,267 | 10 / 12 |
| 2026-11-03 | $-2.13 | $3,826,267 | 10 / 12 |
| 2026-11-04 | $-2.13 | $3,826,267 | 10 / 12 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 10 Hold · 1 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 5 recorded
0 raises · 3 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.